PRECIGEN, INC.
PGENNasdaqHealthcare · Pharmaceutical Preparations · VA · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $9.7M | $3.9M | $6.2M | $26.9M | $14.3M | $32.0M |
| Operating income | −$110.5M | −$135.0M | −$99.8M | — | — | −$16.6M |
| Net income | −$250.6M | −$126.2M | −$95.9M | $28.3M | −$92.2M | −$170.5M |
| Total assets | $155.5M | $145.3M | $151.0M | $216.0M | $359.9M | $314.6M |
| Total liabilities | $134.6M | $78.5M | $32.5M | $89.7M | $252.5M | $247.4M |
| Equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.3M | $67.2M |
| EPS (diluted) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 |
| Shares out. | 294.0M | 248.9M | 252.2M | 206.9M | 205.7M | 169.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1141.1%
- Net margin
- −2588.2%
- Return on equity
- −1198.6%
- Return on assets
- −161.2%
- Return on capital (ROCE)
- −93.5%
- Liabilities / assets
- 86.6%
- Debt / equity
- 6.44×
- Book value / share
- $0.07
- Revenue growth (YoY)
- 146.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -50.41distress
- Accruals / assets
- −104.7%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 10, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2024-06-05Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
- Phase 1Active Not Recruitingreadout ~2024-08-01PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
- Phase 1Active Not Recruitingreadout ~2024-12-15Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Phase 2Recruitingreadout ~2026-11-11PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
- Phase 4Recruitingreadout ~2027-12-02Zopa Retreatment and Vector Shedding in Adults With RRP
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Kirk Randal JActivist (13D)Mar 31, 2026
- Patient Capital Management, LlcPassive (13G)Feb 13, 2026
- Miller William H IiiPassive (13G)Sep 23, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Thomasian Harry Jr.Officer — Chief Financial Officer | May 28, 2026 | Sell | 41,884 | $4.36 |
| Tennant PhilOfficer — Chief Commercial Officer | May 28, 2026 | Sell | 30,272 | $4.36 |
| Shah Rutul ROfficer — Chief Operating Officer | May 28, 2026 | Sell | 42,703 | $4.36 |
| Lehr Donald P.Officer — Chief Legal Officer | May 28, 2026 | Sell | 29,131 | $4.36 |
| Sabzevari HelenOfficer — President and CEO | May 28, 2026 | Sell | 119,250 | $4.36 |
| Thomasian Harry Jr.Officer — Chief Financial Officer | May 23, 2026 | Option exercise | 87,500 | — |
| Tennant PhilOfficer — Chief Commercial Officer | May 23, 2026 | Option exercise | 62,500 | — |
| Shah Rutul ROfficer — Chief Operating Officer | May 23, 2026 | Option exercise | 90,000 | — |
| Sabzevari HelenOfficer — President and CEO | May 23, 2026 | Option exercise | 250,000 | — |
| Lehr Donald P.Officer — Chief Legal Officer | May 23, 2026 | Option exercise | 62,500 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 39.9M | 11.1 | +0.3% |
| Apr 30, 2026 | 39.8M | 14.5 | -0.1% |
| Apr 15, 2026 | 39.8M | 10.8 | +0.3% |
| Mar 31, 2026 | 39.7M | 5.6 | -0.3% |
| Mar 13, 2026 | 39.8M | 10.6 | -5.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Results of operationsMar 25, 2026
- Results of operationsNov 13, 2025
- Unregistered equity saleSep 17, 2025
- Entered a material agreement · New financial obligation · Regulation FD disclosureSep 3, 2025
- Entered a material agreementAug 18, 2025
- Regulation FD disclosureAug 18, 2025
- Director / officer change · Shareholder voteJun 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from PRECIGEN, INC. (1)
- AQUABOUNTY TECHNOLOGIES INCAQBcompletedDec 29, 2016details
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.